The study enrolled 286 first-degree relatives of 151 individuals who had recently been identified as carriers of BRCA1 or BRCA2 mutations. Participants were randomly assigned to one of two pathways. The first was standard of care, in which relatives received a family notification letter alerting them to the mutation in their family and the availability of testing. The second was a facilitated testing program that combined navigation support with streamlined access to genetic testing services. Navigators guided participants through each step of the process, from understanding what the test involves to scheduling appointments and resolving logistical obstacles. The contrast in outcomes between the two groups was immediate and substantial.

At six months, genetic testing uptake among relatives in the facilitated testing group had risen to 73 percent, compared with 51 percent among those who received the standard notification letter — a 43 percent relative increase in testing. By eighteen months, 90 percent of relatives in the facilitated testing group had completed genetic testing. These numbers matter because cascade genetic testing, the systematic process of offering testing to family members of a known mutation carrier, is one of the most powerful tools in precision oncology. It converts a single molecular diagnosis into a family-wide risk assessment, allowing preventive measures to be targeted precisely at those who need them.

The biological stakes are well established. BRCA1 and BRCA2 are tumor suppressor genes involved in repairing DNA double-strand breaks through homologous recombination. When one copy of either gene carries a pathogenic mutation, cells lose a critical layer of genomic maintenance, and the accumulation of additional defects can drive malignant transformation. Women with pathogenic BRCA variants face markedly elevated risks of breast and ovarian cancer, while men carrying these mutations face increased risks of prostate cancer and, in the case of BRCA2, male breast cancer. Identifying carriers early opens the door to intensified surveillance, risk-reducing surgery, and in some settings targeted therapeutic strategies should cancer develop.

The trial’s results underscore a point that oncologists and genetic counselors have long suspected: information alone is insufficient. A letter explaining inherited risk, however clearly written, leaves the burden of action entirely on the recipient. Relatives must interpret the implications, contact a provider, verify insurance coverage, arrange testing and then follow up on results. Each step is an opportunity for confusion, delay or abandonment. Concerns about cost, uncertainty about the process and difficulty accessing specialized genetics services are among the barriers that have kept cascade testing rates stubbornly low despite decades of growing genetic literacy.

“This study demonstrates that simply informing relatives of their inherited cancer risk is not enough,” said Roni Wilke, M.D., assistant professor of Gynecologic Oncology & Reproductive Medicine at MD Anderson. “When we provided navigation to help people through the testing process, we noticed a meaningful difference in utilization and how soon people completed their testing. This creates new opportunities to enhance screening, prevention and early intervention for several hereditary cancers.” The quote captures the central design insight of the trial: the intervention did not change what relatives were told, but how they were helped to act on it.

Among the 206 relatives who ultimately completed testing, the yield of clinically significant findings was striking. Forty-six percent were found to carry a BRCA1 or BRCA2 mutation associated with a higher risk of cancer, and of those carriers, 86 percent harbored the same familial BRCA mutation that had been identified in their relative. In other words, nearly half of the tested relatives learned they carried a mutation with direct implications for their own cancer surveillance and prevention, and the overwhelming majority of positive results reflected the known family variant rather than an unrelated one. This confirms that when cascade testing is completed at scale, it reliably identifies the intended at-risk individuals.

The implications extend beyond the BRCA genes themselves. Hereditary cancer syndromes involving other genes, such as those linked to Lynch syndrome and familial polyposis, follow a similar cascade logic: one diagnosis in a family member should trigger systematic risk assessment across the kindred. If navigation and facilitation can lift BRCA cascade testing from roughly half of eligible relatives to nine in ten within eighteen months, the same model could plausibly be adapted to other hereditary cancer pathways, multiplying the preventive value of every positive germline result returned by a clinical genetics laboratory.

From a health systems perspective, the trial addresses a well-documented translational gap. Genetic testing technology has become faster and cheaper, and laboratories routinely return results within weeks, yet the downstream work of reaching relatives has lagged. Family notification letters remain the default in many institutions because they are inexpensive and scalable, but the new data suggest that their passive nature leaves substantial value unrealized. Navigation programs require personnel and coordination, costs that health systems and insurers will need to weigh against the potential savings from cancers prevented or detected at earlier, more treatable stages.

For families affected by hereditary cancer, the message of the study is practical and hopeful. Knowing that a BRCA mutation runs in the family is the starting point, not the finish line. Structured support — a navigator who explains the process, helps schedule testing and keeps the momentum going — transformed intention into action for the large majority of relatives in the trial. As genetic information becomes an ever more routine part of cancer care, ensuring that it travels meaningfully through families may prove as important as the sequencing itself, turning individual diagnoses into opportunities for prevention across entire kindreds.

Subject of Research: Cascade genetic testing for hereditary BRCA-related cancers among first-degree relatives

Article Title: Personalized support and navigation increased genetic testing of hereditary cancers among immediate family members

Article References: Personalized support and navigation increased genetic testing of hereditary cancers among immediate family members. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: BRCA1, BRCA2, cascade genetic testing, hereditary cancer, genetic counseling, patient navigation, cancer prevention, MD Anderson Cancer Center, Journal of Clinical Oncology, randomized trial, first-degree relatives, precision oncology

Germline genetic testing examines DNA inherited from a person’s parents, typically using blood or saliva samples, to identify alterations known as germline pathogenic variants. These variants are present in every cell of the body and can predispose carriers to cancer. Detecting them matters for two reasons. First, certain inherited variants have direct treatment implications, informing decisions about targeted therapies, surgical options, and surveillance strategies. Second, identifying a pathogenic variant in a patient opens the door to cascade testing, in which relatives are offered testing to determine whether they carry the same variant and therefore face elevated cancer risk themselves. In clinical practice, however, germline screening has traditionally been reserved for patients diagnosed before age 50, reflecting an assumption that cancers arising later in life are less likely to be driven by inherited predisposition.

Zsofia K. Stadler, clinical director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, and Luis A. Diaz, Jr., head of Solid Tumor Oncology at the same institution, served as co-corresponding authors of the study. Stadler explained that the logic behind the age cutoff rests on the idea that patients with average- or late-onset cancers are less likely than those with early-onset disease to have cancers caused by inherited pathogenic variants. But she argued that this reasoning has hardened into a barrier that keeps many eligible patients from receiving potentially life-changing information. In a statement accompanying the study, she described current standard practice as, in many ways, a gatekeeper for genetic testing, and said the research team set out to quantify how much inherited cancer risk is missed when age at diagnosis is weighted too heavily.

To answer that question, the researchers performed germline genetic testing on all 39,184 patients with solid tumors seen at Memorial Sloan Kettering Cancer Center, without applying any age restriction. Testing was carried out using the MSK-Integrated Mutation Profiling of Actionable Targets, or MSK-IMPACT, assay, which analyzed DNA isolated from patients’ blood or saliva for 94 genes implicated in inherited cancer predisposition. This universal approach allowed the team to compare the actual prevalence of pathogenic variants across the entire patient population with what would have been captured under the conventional age-limited strategy.

The results were striking. Overall, 16.3 percent of all patients in the cohort harbored at least one germline pathogenic variant. When the researchers modeled what would have happened under the typical practice of restricting testing to patients under age 50, they calculated that 4,601 patients with pathogenic variants would have been excluded, amounting to 72 percent of all carriers in the cohort. In other words, the majority of patients carrying inherited cancer risk variants would never have been identified through the standard approach, leaving them without the clinical and familial benefits that come from knowing their genetic status.

The team then took a more nuanced look at how variant prevalence varies with the age at which cancer develops. Rather than relying on the standard convention of labeling any cancer diagnosed before age 50 as early-onset regardless of type, the researchers classified each patient’s cancer as early-, average-, or late-onset according to the distribution of age at onset for that specific cancer type. Early-onset was defined as occurring more than one standard deviation below the mean age at onset for the cancer type, late-onset as more than one standard deviation above the mean, and average-onset as falling within one standard deviation of the mean. This cancer-specific classification acknowledged that the typical age of diagnosis varies widely across malignancies, from relatively young ages in some tumors to much older ages in others.

Using this framework, the prevalence of germline pathogenic variants was 18.4 percent among patients with early-onset cancers, 15.6 percent among those with average-onset cancers, and 12.3 percent among those with late-onset cancers. The decline with age was real, but far shallower than the age-based testing policy presumes. Even among patients whose cancers appeared late relative to the norm for their tumor type, more than one in ten carried an inherited pathogenic variant, a prevalence high enough to carry substantial clinical consequence.

The distinction between variant categories sharpened the picture further. High-penetrance variants, which are more likely to produce the cancer-predisposing effect with which they are associated, occurred in 9.1 percent of patients with early-onset cancers, 5.5 percent of those with average-onset cancers, and 2.6 percent of those with late-onset cancers. Moderate-penetrance variants showed a flatter distribution, appearing in 3.3 percent, 3.4 percent, and 2.5 percent of early-, average-, and late-onset cases respectively. Taken together, high- and moderate-penetrance pathogenic variants, which carry potential implications for cancer treatment strategies, were found in about 9.7 percent of all patients in the cohort. According to Stadler, the persistence of these clinically actionable variants among older patients demonstrated that a uniform screening cutoff at age 50 is insufficient, and she emphasized that the study showed the value of universal germline genetic testing regardless of age.

The authors argue that the findings should reshape clinical standards. Hereditary cancer can occur at any age, Diaz said, and the field should move toward a new standard in which genetic testing is considered for every patient diagnosed with cancer, regardless of age. He noted that the manuscript shows relying on age at diagnosis misses a substantial proportion of patients with germline pathogenic variants and provides strong support for moving toward universal germline genetic testing in patients with cancer. Stadler added that universal testing would give clinicians insights into a patient’s cancer that could guide treatment, while also enabling greater use of cascade testing among relatives. She cautioned, however, that cascade testing remains one of the most underused opportunities in cancer prevention, noting that once a hereditary cancer predisposition variant is identified in one patient, testing relatives becomes highly targeted and informative, yet only a minority of eligible relatives currently undergo testing.

As with any single-institution study, the findings come with caveats that the authors themselves acknowledged. The research was conducted at one major tertiary cancer center, a setting that may not reflect the demographics or referral patterns of community oncology practices. Certain cancer types were over- or underrepresented in the cohort, and the patient population was predominantly of European and Ashkenazi Jewish ancestry, both groups in which certain founder pathogenic variants are relatively common. Generalizing the results to more diverse populations will require further study. The work was funded by grants from the National Institutes of Health and Memorial Sloan Kettering Cancer Center, and the authors disclosed a range of professional relationships and intellectual property interests in keeping with journal policy. Even with these limitations, the scale of the dataset and the magnitude of the gap it exposes, nearly three-quarters of variant carriers overlooked by age-based rules, make a compelling case that the era of age-restricted germline testing in oncology may be drawing to a close, with universal testing poised to become the new benchmark of care.

Subject of Research: Universal germline genetic testing for inherited cancer risk in patients with solid tumors

Article Title: Current age-based genetic testing in patients with cancer may miss majority of inherited gene variants

Article References: Current age-based genetic testing in patients with cancer may miss majority of inherited gene variants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: germline genetic testing, hereditary cancer, pathogenic variants, cancer predisposition, age cutoff, universal testing, cascade testing, MSK-IMPACT, solid tumors, Cancer Discovery, Memorial Sloan Kettering, precision oncology

The headline finding is deceptively simple: CPM rates barely moved. In the earlier cohort, 19 percent of women had their healthy opposite breast removed at the time of cancer surgery; in the later cohort, the figure was 15 percent, a statistically significant but clinically modest decline that leaves roughly one in seven patients still undergoing a procedure that society guidelines explicitly discourage for average-risk women. The study period is particularly instructive because it brackets the 2016 consensus statement, which synthesized data showing that CPM produces only a small absolute reduction in contralateral breast cancer and no demonstrated survival benefit for most patients. Subsequent work has reinforced that message, including a 2024 analysis in JAMA Oncology reporting that bilateral mastectomy did not improve breast cancer mortality, and a Society of Surgical Oncology statement published the same year laying out narrow indications, outcomes, and risks for contralateral mastectomy. Yet the Kentucky and Minnesota data show that the practice, once entrenched, has proven resistant to guideline-driven de-escalation.

The technical details of the study design matter for interpreting these numbers. Because the analysis was a retrospective chart review rather than a randomized trial, it captures real-world practice patterns but cannot establish causation between the 2016 statement and any change in surgical behavior. The two cohorts were defined by diagnosis date, and the researchers evaluated not only CPM rates but also the uptake of genetic testing and the clinical and demographic factors associated with the decision to remove the contralateral breast. The institutions are both academic health systems, which typically have greater access to genetic counseling and multidisciplinary tumor boards than community hospitals, making the persistence of high CPM rates all the more notable. If guideline concordance is difficult to achieve in settings with robust resources, the authors suggest, the challenge in broader practice may be even greater.

The most dramatic change between the two eras was not in the operating room but in the genetics laboratory. Before 2016, only 2 percent of the women in the study underwent genetic testing; from 2016 onward, that figure rose to 22 percent. This eleven-fold increase reflects the second major consensus statement from the American Society of Breast Surgeons, published in 2019, which recommended that genetic testing be made available to all patients with breast cancer, not merely those meeting traditional family-history criteria. The expansion was enabled by broader panel testing that now screens for a growing list of moderate-penetrance genes such as ATM, CHEK2, and PALB2 in addition to the high-risk BRCA1 and BRCA2 genes. Wider testing has real clinical value, identifying carriers who benefit from intensified surveillance or risk-reducing surgery, but it has also complicated surgical decision-making, because the contralateral breast cancer risk associated with many moderate-risk variants remains imprecisely quantified.

Genetic testing emerged as one of the strongest factors associated with receiving a CPM in this cohort. That association cuts both ways. For women found to carry a pathogenic variant with a substantially elevated contralateral risk, such as BRCA1 or BRCA2, prophylactic removal of the unaffected breast is guideline-supported and can meaningfully reduce second cancer risk, as established by long-term studies of mutation carriers. But prior research has shown that testing results often arrive too late in the surgical pathway to change decisions, and that many women with negative test results still proceed with CPM. Studies of rapid preoperative testing have demonstrated that timely results can de-escalate surgery among carriers, yet the present findings suggest that in routine practice, testing more often accompanies, rather than redirects, the decision toward more extensive surgery. The authors point to this timing problem as a key target for intervention.

The demographic and tumor characteristics associated with CPM form a familiar but troubling pattern. Younger age at diagnosis, white race, lobular histology, increasing tumor size, and HER2 positivity all independently predicted receipt of the procedure. The age effect is consistent with a large body of literature showing that younger women more frequently overestimate their risk of a contralateral cancer and place greater weight on future risk when making surgical choices. The racial disparity is more concerning: prior national analyses have documented that white patients are disproportionately likely to undergo CPM even after accounting for clinical factors, raising questions about equitable counseling and access to reconstruction. The association with lobular histology likely reflects both the genuine difficulty of surveillance in lobular carcinoma, which is harder to detect mammographically, and the tendency of lobular cancers to be multifocal, which may amplify patient and physician concern about the opposite breast.

The persistence of CPM despite discouraging guidelines is not unique to this study. Analyses from the National Cancer Data Base and from state and national registries documented the steep rise of the procedure through the 2000s, and subsequent single-institution and multi-institution studies have repeatedly found that rates plateaued rather than fell after 2016. Research examining the effect of the American Society of Breast Surgeons guidelines specifically, including work published in Annals of Surgical Oncology and in Surgery, reached similar conclusions: the statements changed the conversation but not, for the most part, the operations. Patient-driven factors appear central. Surveys have shown that many women who choose CPM report high satisfaction with the decision, and studies of patient reactions to surgeon recommendations indicate that surgeon advice is only one input among many, with fear of recurrence and a desire for symmetry after reconstruction playing powerful roles.

The clinical stakes of this disconnect are considerable. CPM is a major operation that extends anesthesia time, increases the risk of surgical complications, lengthens recovery, and can compromise or delay reconstruction, all for a benefit that for average-risk women is largely psychological rather than survival-related. Quality-of-life studies comparing breast conservation with mastectomy and reconstruction have generally found comparable or better long-term outcomes with the less aggressive approach, and decision analyses have shown that the survival gain from CPM in average-risk women is measured in fractions of a percent. At the same time, the rise of multigene panel testing means that a minority of patients genuinely benefit from the procedure, which complicates blanket discouragement and may partly explain why surgeons remain reluctant to refuse a requested CPM outright. The clinical challenge is discriminating between the woman whose panel result justifies bilateral surgery and the woman whose fear, not genetics, is driving the request.

The authors are explicit that their findings should catalyze further work rather than close the question. They call for research to understand why CPM rates have remained stable across the guideline era and to identify interventions capable of reducing rates in average-risk women. Candidate strategies suggested by the broader literature include moving genetic testing earlier in the diagnostic pathway so that results can inform the initial surgical plan, standardizing risk counseling with validated tools that communicate contralateral risk in absolute rather than relative terms, and engaging surgeons in shared decision-making frameworks that acknowledge patient values while presenting the evidence clearly. Whether such interventions can succeed where consensus statements have not remains an open question, but the two-institution data provide a clear baseline: a decade after professional societies said the procedure should be rare, one in seven women was still having it.

For patients, the practical message is that a new breast cancer diagnosis is a moment when surgical decisions are made quickly and often under emotional strain, and that the evidence favors restraint for most women. A contralateral cancer diagnosed at an early stage is generally treatable, modern systemic therapies reduce contralateral risk further, and removing the healthy breast does not improve survival for the average patient. For women with documented pathogenic variants, the calculus is different and genetic counseling is essential. The study’s most valuable contribution may be its demonstration that guidelines alone do not change practice, and that closing the gap between evidence and the operating room will require changes to how, and how early, genetic information reaches the surgical decision.

Subject of Research: Trends in contralateral prophylactic mastectomy and genetic testing among women with unilateral breast cancer following society guideline publications

Article Title: Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines

Article References: Reagan, A. M., Rutherford, C. R., Prathibha, S., Levy, B. E., Praska, C., Thacker, S. E., Kolbow, M., Ozed-Williams, B., Karnik, K. N., Mangino, A. A., Marmor, S., Tuttle, T. M., Hui, J. Y. C., & Burke, E. E. (2026). Trends in contralateral prophylactic mastectomy and genetic testing in the era of new society guidelines. Breast Cancer Research and Treatment, 219(3), Article 14. https://doi.org/10.1007/s10549-026-08073-6

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08073-6

Keywords: contralateral prophylactic mastectomy, breast cancer, genetic testing, BRCA, surgical guidelines, American Society of Breast Surgeons, unilateral breast cancer, genetic counseling, mastectomy rates, breast cancer surgery, hereditary cancer, surgical decision making